AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28736268 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 145
Study 28736268 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment
Number of subjects: 145
Study 26871270 — intervention group
Group type: EXPERIMENTAL
Intervention: Otelixizumab
Number of subjects: 161
Study 26871270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 24666558 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized training group
Number of subjects: 61
Study 24666558 — intervention group
Group type: COMPARATOR
Intervention: Non-individualized training group
Number of subjects: 61
Study 22940511 — intervention group
Group type: EXPERIMENTAL
Intervention: Home‐based individualized exercise program (HBIEP)
Number of subjects: 187
Study 22940511 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 187
Study 22940511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 187
Study 20193794 — intervention group
Group type: COMPARATOR
Intervention: CPVA (Circumferential Pulmonary Vein Ablation) group, n = 73
Number of subjects: 146
Study 20193794 — intervention group
Group type: EXPERIMENTAL
Intervention: CPVA-CM (Circumferential Pulmonary Vein Ablation with Circular Mapping catheter) group, n = 73
Number of subjects: 146
Study 18390799 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.i.d.)
Number of subjects: 38
Study 18390799 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose oral contraceptive pill (OCP) (35 microg ethinyl estradiol/2 mg cyproterone acetate)
Number of subjects: 38
Study 18390799 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (17 weight-matched)
Number of subjects: 38
Study 15531357 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-consensual kiss condition (audiotape description)
Number of subjects: 121
Study 15531357 — intervention group
Group type: COMPARATOR
Intervention: Consensual kiss condition (audiotape description)
Number of subjects: 121
Study 12464458 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-free amino acid drink (TFD)
Number of subjects: 8
Study 12464458 — intervention group
Group type: COMPARATOR
Intervention: Control drink containing tryptophan
Number of subjects: 8
Study 10631438 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1% (n = 7)
Number of subjects: 16
Study 10631438 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2% (n = 9)
Number of subjects: 16
Study 7577204 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide, cisplatin, and carmustine with autologous bone marrow support
Number of subjects: 0
Study 7577204 — intervention group
Group type: COMPARATOR
Intervention: Low-dose cyclophosphamide, cisplatin, and carmustine
Number of subjects: 0
Study 1663851 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for back pain
Number of subjects: 0
Study 1663851 — intervention group
Group type: COMPARATOR
Intervention: Retest at one‐to‐two week intervals
Number of subjects: 0
Study 1663851 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status instruments
Number of subjects: 0
Study 7214801 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 16
Study 7214801 — intervention group
Group type: COMPARATOR
Intervention: Sodium methyl-glucamine diatrizoate (ionic medium)
Number of subjects: 16
Study 30367541 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal glasses
Number of subjects: 119
Study 30367541 — intervention group
Group type: COMPARATOR
Intervention: Unifocal glasses
Number of subjects: 119
Study 28421317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) - 250 ml of Arginaid Water ingested in the evening before the experiment and at 7:00 am on the day of the experiment.
Number of subjects: 14
Study 28421317 — intervention group
Group type: COMPARATOR
Intervention: Control group - fasting after dinner and drinking only water until 7:00 am on the day of the experiment.
Number of subjects: 14
Study 28421317 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplement (ONS) - 250 ml of Arginaid Water.
Number of subjects: 14
Study 28421317 — intervention group
Group type: COMPARATOR
Intervention: Control group - fasting and drinking only water.
Number of subjects: 14
Study 26556021 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension band wiring (TBW)
Number of subjects: 80
Study 26556021 — intervention group
Group type: COMPARATOR
Intervention: Hook plate (HP)
Number of subjects: 80
Study 23480975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 26
Study 23480975 — intervention group
Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 26
Study 21219660 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 80 mcg and albuterol 400 mcg
Number of subjects: 5783
Study 21219660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5783
Study 19395131 — intervention group
Group type: EXPERIMENTAL
Intervention: Isohumulones 32 mg
Number of subjects: 94
Study 19395131 — intervention group
Group type: EXPERIMENTAL
Intervention: Isohumulones 48 mg
Number of subjects: 94
Study 19395131 — intervention group
Group type: EXPERIMENTAL
Intervention: Isohumulones 16 mg
Number of subjects: 94
Study 19395131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 17948074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g on the night before surgery and 1 g twice daily for 5 days after surgery)
Number of subjects: 100
Study 17948074 — intervention group
Group type: COMPARATOR
Intervention: Control (no ascorbic acid)
Number of subjects: 100
Study 15711820 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (postoperative enteral feeding including synbiotics)
Number of subjects: 54
Study 15711820 — intervention group
Group type: COMPARATOR
Intervention: Control (enteral feeding only)
Number of subjects: 54
Study 15711820 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 54
Study 15711820 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 12202015 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg qd plus sertraline 50 mg qd
Number of subjects: 13
Study 12202015 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone 50 mg qd with placebo
Number of subjects: 13
Study 9818688 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/day)
Number of subjects: 26
Study 9818688 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (5 microg/kg/day)
Number of subjects: 26
Study 9818688 — intervention group
Group type: COMPARATOR
Intervention: Both G-CSF and GM-CSF
Number of subjects: 26
Study 8580921 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoic acid (n = 32)
Number of subjects: 54
Study 8580921 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 54
Study 2653593 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg.kg‐1)
Number of subjects: 6
Study 2653593 — intervention group
Group type: COMPARATOR
Intervention: Control (no prior exercise)
Number of subjects: 6
Study 2653593 — intervention group
Group type: COMPARATOR
Intervention: 24 h postexercise
Number of subjects: 6
Study 2653593 — intervention group
Group type: COMPARATOR
Intervention: 48 h postexercise
Number of subjects: 6
Study 76166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg at bedtime)
Number of subjects: 45
Study 76166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30272538 — intervention group
Group type: EXPERIMENTAL
Intervention: GMT+WMT
Number of subjects: 18
Study 30272538 — intervention group
Group type: COMPARATOR
Intervention: WMT
Number of subjects: 18
Study 30939922 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated hovering intervention with patient-level incentives for daily weight monitoring and diuretic adherence, combined with automated feedback into the clinical care pathway.
Number of subjects: 0
Study 30939922 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 0
Study 29335840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary access
Number of subjects: 174
Study 29335840 — intervention group
Group type: COMPARATOR
Intervention: Subclavian approach
Number of subjects: 174
Study 29335840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided axillary access (when subclavian failed)
Number of subjects: 174
Study 29335840 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead complications
Number of subjects: 174
Study 27817819 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 100 μg OD
Number of subjects: 371
Study 27817819 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 100 μg BD
Number of subjects: 371
Study 27817819 — intervention group
Group type: EXPERIMENTAL
Intervention: FP 250 μg BD
Number of subjects: 371
Study 27817819 — intervention group
Group type: COMPARATOR
Intervention: FF/VI 100/25 μg OD
Number of subjects: 371
Study 27817819 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal due to worsening asthma
Number of subjects: 371
Study 27817819 — intervention group
Group type: COMPARATOR
Intervention: Adverse events
Number of subjects: 371
Study 24809261 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular blocking agents (NMBA) - vecuronium, loading dose of 0.1 mg/kg, continuous infusion of 0.05 mg/kg/h for 24-48 hours
Number of subjects: 96
Study 24809261 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NMBA treatment)
Number of subjects: 96
Study 22713257 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based HIV counselling and testing (HBHCT) programme
Number of subjects: 2964
Study 19318295 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac epolamine patch
Number of subjects: 220
Study 19318295 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 220
Study 17311621 — intervention group
Group type: EXPERIMENTAL
Intervention: Viusid (three sachets daily) + IFN alpha‐2b (5 MU on alternate days) + ribavirin (13 mg/kg daily)
Number of subjects: 100
Study 17311621 — intervention group
Group type: COMPARATOR
Intervention: IFN alpha‐2b (5 MU on alternate days) + ribavirin (13 mg/kg daily)
Number of subjects: 100
Study 17311621 — intervention group
Group type: EXPERIMENTAL
Intervention: Viusid
Number of subjects: 100
Study 17311621 — intervention group
Group type: COMPARATOR
Intervention: Without Viusid
Number of subjects: 100
Study 17311621 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (without Viusid)
Number of subjects: 100
Study 15500398 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxypurinol added to standard therapy
Number of subjects: 0
Study 15500398 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 11174617 — intervention group
Group type: EXPERIMENTAL
Intervention: Early indomethacin treatment (3 x 0.2 mg/kg every 12 hours, starting on day 3)
Number of subjects: 127
Study 11174617 — intervention group
Group type: EXPERIMENTAL
Intervention: Early indomethacin treatment
Number of subjects: 127
Study 11174617 — intervention group
Group type: COMPARATOR
Intervention: Late indomethacin treatment (starting on day 7)
Number of subjects: 127
Study 9747547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention GPs (received the intervention)
Number of subjects: 150
Study 9747547 — intervention group
Group type: COMPARATOR
Intervention: Control GPs (did not receive the intervention)
Number of subjects: 150
Study 9747547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention GPs (47% complied with the intervention)
Number of subjects: 150
Study 9747547 — intervention group
Group type: EXPERIMENTAL
Intervention: Legibility and doctor's assessment determination
Number of subjects: 150
Study 8111598 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC)
Number of subjects: 320
Study 3387686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 100 mg and acetylcysteine 100 mg every 6 h
Number of subjects: 8
Study 3387686 — intervention group
Group type: COMPARATOR
Intervention: Acetylcysteine 100 mg every 6 h
Number of subjects: 8
Study 30720579 — intervention group
Group type: EXPERIMENTAL
Intervention: TN at ST36
Number of subjects: 18
Study 30720579 — intervention group
Group type: COMPARATOR
Intervention: TN at PTN
Number of subjects: 18
Study 30106531 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency sonic power toothbrush (A)
Number of subjects: 120
Study 30106531 — intervention group
Group type: COMPARATOR
Intervention: Oscillating-rotating power toothbrush (B)
Number of subjects: 120
Study 30106531 — intervention group
Group type: COMPARATOR
Intervention: Traditional sonic toothbrush (C)
Number of subjects: 120
Study 28150367 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% benzoyl peroxide gel
Number of subjects: 458
Study 28150367 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 458
Study 25535265 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief relationship abuse education and counseling intervention
Number of subjects: 1011
Study 25535265 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care control condition
Number of subjects: 1011
Study 23247716 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient of 8%
Number of subjects: 18
Study 23247716 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing gradient
Number of subjects: 18
Study 23247716 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill cycling
Number of subjects: 18
Study 21620906 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 14
Study 21620906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18465329 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1000
Study 16572117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (2 mug/kg min)
Number of subjects: 40
Study 16572117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15071246 — intervention group
Group type: EXPERIMENTAL
Intervention: Bachmann's Bundle pacing
Number of subjects: 0
Study 15071246 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage pacing
Number of subjects: 0
Study 15670701 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of prosodic expressions of emotions using fMRI
Number of subjects: 0
Study 15670701 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonetic monitoring of emotional tone stimuli using fMRI
Number of subjects: 0
Study 15670701 — intervention group
Group type: COMPARATOR
Intervention: Comparison of activation maps between emotional tone recognition and phonetic monitoring
Number of subjects: 0
Study 10628612 — intervention group
Group type: EXPERIMENTAL
Intervention: Opti‐Q from Abbott
Number of subjects: 44
Study 10628612 — intervention group
Group type: COMPARATOR
Intervention: IntelliCath from Baxter
Number of subjects: 44
Study 7495202 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T 380A (TCU 380A)
Number of subjects: 3
Study 7495202 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload copper 375 (MLCU 375)
Number of subjects: 3
Study 7495202 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload copper 250 (MLCU 250)
Number of subjects: 3
Study 2143890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion (HAI) chemotherapy
Number of subjects: 0
Study 2143890 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) administration
Number of subjects: 0
Study 7285484 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg
Number of subjects: 8
Study 7285484 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 15 mg
Number of subjects: 8
Study 7285484 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 25 mg
Number of subjects: 8
Study 7285484 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg d-amphetamine)
Number of subjects: 8
Study 30744571 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and self-management intervention
Number of subjects: 18
Study 30744571 — intervention group
Group type: EXPERIMENTAL
Intervention: Headache classification interview
Number of subjects: 18
Study 30744571 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment from primary care
Number of subjects: 18
Study 28488178 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin colonoscope (UTC)
Number of subjects: 270
Study 28488178 — intervention group
Group type: COMPARATOR
Intervention: Pediatric colonoscope
Number of subjects: 270
Study 25351237 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 µg/kg DEX in 10 mL isotonic saline (group II)
Number of subjects: 90
Study 25351237 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 µg/kg DEX in 10 mL isotonic saline (group III)
Number of subjects: 90
Study 25351237 — intervention group
Group type: COMPARATOR
Intervention: 10 mL isotonic saline (group I)
Number of subjects: 90
Study 23551935 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg/day
Number of subjects: 164
Study 23551935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 21464680 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 counseling callbacks
Number of subjects: 1923
Study 21464680 — intervention group
Group type: COMPARATOR
Intervention: 4 counseling callbacks
Number of subjects: 1923
Study 19587624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 81
Study 19587624 — intervention group
Group type: COMPARATOR
Intervention: Loss of resistance (LOR)
Number of subjects: 81
Study 17021811 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued thiamazole medication (11.0+/‐7.0 mg/day)
Number of subjects: 316
Study 17021811 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of thiamazole for 2 days
Number of subjects: 316
Study 17021811 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of thiamazole for 1 day
Number of subjects: 316
Study 15148204 — intervention group
Group type: EXPERIMENTAL
Intervention: Single piece SA30AL IOL
Number of subjects: 20
Study 15148204 — intervention group
Group type: COMPARATOR
Intervention: Three piece MA30BA IOL
Number of subjects: 20
Study 11534564 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min steady state test
Number of subjects: 62
Study 11534564 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐min steady state test
Number of subjects: 62
Study 11534564 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry with 5‐min steady state test
Number of subjects: 62
Study 11534564 — intervention group
Group type: EXPERIMENTAL
Intervention: Time required for 5‐min steady state data collection
Number of subjects: 62
Study 9780135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine administration
Number of subjects: 6
Study 9780135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine administration
Number of subjects: 6
Study 9780135 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine administration
Number of subjects: 6
Study 7825033 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC co-cultivated with phytohemagglutinin‐P activated PBMC from healthy, HIV‐1 antibody negative donors
Number of subjects: 36
Study 7825033 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC from individuals with concomitant p24 antigenemia
Number of subjects: 36
Study 7825033 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture positive, p24 antigenemic patients
Number of subjects: 36
Study 7825033 — intervention group
Group type: EXPERIMENTAL
Intervention: p24 serum negative cases with CD4+ counts of < 500 cells/mm3
Number of subjects: 36
Study 29288250 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (250,000 or 500,000 IU)
Number of subjects: 30
Study 29288250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25531677 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 587
Study 25531677 — intervention group
Group type: COMPARATOR
Intervention: Control (oral glucose-lowering drugs excluding TZD)
Number of subjects: 587
Study 24045120 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) needle
Number of subjects: 72
Study 24045120 — intervention group
Group type: COMPARATOR
Intervention: Conventional (BRK-1) needle
Number of subjects: 72
Study 21327593 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated pulse therapy of methylprednisolone (1 g for 3 days) and cyclophosphamide (15 mg/kg per day for 2 days), followed by dexamethasone (5 mg every 6 hours) until PaO2 >80 mmHg or repeated 1 g MP for 3 days and 1 g CP for 1 day if PaO2 <60 mmHg
Number of subjects: 111
Study 21327593 — intervention group
Group type: COMPARATOR
Intervention: High doses of cyclophosphamide (2 mg/kg per day) and dexamethasone (5 mg every 6 hours) for 14 days
Number of subjects: 111
Study 18685945 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.01 mg x kg(‐1) x min(‐1)
Number of subjects: 59
Study 18685945 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.02 mg x kg(‐1) x min(‐1)
Number of subjects: 59
Study 18685945 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.03 mg x kg(‐1) x min(‐1)
Number of subjects: 59
Study 18685945 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol 0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1)
Number of subjects: 59
Study 16573799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (single dose)
Number of subjects: 43
Study 16573799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose (long-term administration)
Number of subjects: 43
Study 16573799 — intervention group
Group type: COMPARATOR
Intervention: Saccharomyces boulardii
Number of subjects: 43
Study 15339557 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization (TACE) and traditional Chinese medicine (TCM)
Number of subjects: 39
Study 15339557 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE)
Number of subjects: 39
Study 10712318 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin (7.5 mg/kg every 8 h)
Number of subjects: 298